Imbruvica
AbbVie writes off $2.1B for Imbruvica amid CMS pricing pressure
Anika Sharma
The introduction of BeiGene’s groundbreaking oral treatment, Brukinsa, has taken a toll on the sales of AbbVie and Johnson & ...
AbbVie Raises Profit Expectations Despite Q2 Decrease in Humira and Imbruvica Sales
SG Tylor
AbbVie executives express satisfaction with the introduction of Humira biosimilars in the US, despite facing significant revenue declines for both ...
In a heated dispute over blood cancer treatment, AbbVie sues BeiGene over a brand-new Imbruvica patent
SG Tylor
AbbVie’s Pharmacyclics division claims that BeiGene’s Bruki Nsa violates a patent on its blood cancer medication Imbruvica in a recent ...
